A Pennsylvania Risperdal lawsuit has reportedly been settled for an undisclosed amount. According to The Legal Intelligencer, the gynecomastia case had been scheduled to go to trial on May 9th in the Philadelphia Court of Common Pleas, but was resolved on May 13th.

The lawsuit was one of more than 1,700 Risperdal cases now pending in a mass tort litigation underway in Philadelphia. All of the complaints were filed on behalf of men and boys who allegedly experienced excessive male breast growth – a condition known as gynecomastia – due to their use of the antipsychotic medication.  Plaintiffs claim that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed information about the link between Risperdal and gynecomastia, and failed to provide doctors and patients with adequate warnings about the possibility of breast growth in males using the antipsychotic medication.

The Court has scheduled at least 12 Risperdal claims for trial this year. The next is set to begin on June 20th, while the final trial has been schedule for November.

Global Risperdal Settlement Unlikely for Now

Last year, four Risperdal gynecomastia cases were heard by juries. The first concluded in February 2015, after the plaintiff was awarded $2.5 million in compensation for his excessive breast growth. The second ended a month later, after that jury found that Risperdal had not caused the plaintiff’s gynecomastia, though it did rule that Johnson & Johnson was negligent for failing to warn about this potential risk. A third case resulted in a $1.75 million verdict for the plaintiff, while a fourth was awarded $500,000.

A Risperdal settlement was also reached in a case scheduled to go to trial in May 2015, on the very day opening arguments were to begin. The terms of that accord have not been disclosed.

According to The Legal Intelligencer, the past and future trials are considered to be bellwether cases, and could ultimately help shape a future global settlement. However, it does not appear that such a resolution is imminent, with one plaintiffs’ attorney characterizing the settlements struck so far as “one-offs.”

“There is no indication of [Johnson & Johnson’s] current interest in settlement, which leads us to continue the litigation in trial mode,” the attorney told the Legal Intelligencer.  “There’s no global settlement talks.”

Contact an Attorney about a Risperdal Lawsuit

Bernstein Liebhard LLP continues to evaluate Risperdal lawsuits involving gynecomastia. To learn more, please contact our office by calling 877-779-1414.

Published May 24, 2016 by